Literature DB >> 26460255

A founder effect for p47(phox)Trp193Ter chronic granulomatous disease in Kavkazi Jews.

Martin de Boer1, Shay Tzur2, Karin van Leeuwen1, Paula C D Dencher1, Karl Skorecki2, Baruch Wolach3, Ronit Gavrieli3, Ivane Nasidze4, Mark Stoneking4, Michael W T Tanck5, Dirk Roos6.   

Abstract

Chronic granulomatous disease (CGD) is a rare congenital immune deficiency caused by mutations in any of the five genes encoding NADPH oxidase subunits. One of these genes is NCF1, encoding the p47(phox) protein. A group of 39 patients, 14 of whom are of Kavkazi Jewish descent, was investigated for a founder effect for the mutation c.579G>A (p.Trp193Ter) in NCF1. We analyzed various genetic markers in the NCF1 region, including two single nucleotide polymorphisms (SNPs) in NCF1 and two short tandem repeats (STRs) located near NCF1. Most patients were homozygous for the c.579G>A mutation, but three patients were hemizygotes, with a deletion of NCF1 on the other allele, and three patients were compound heterozygotes with another mutation in NCF1. All Kavkazi Jewish patients had a c.295G_c.345T SNP combination in NCF1 and shared a common number of repeats in STR3. In addition, 90% of the Kavkazi Jewish patients shared a common number of repeats in STR1. This uniformity indicates that the c.579G>A mutation in NCF1 was introduced some 1200-2300 years ago in the Kavkazi Jewish population. Variation amongst the other investigated populations from the Middle East indicates that this mutation exists in these non-Kavkazi populations already for more than 5000 years.
Copyright © 2015. Published by Elsevier Inc.

Entities:  

Keywords:  Chronic granulomatous disease; Founder effect; Kavkazi Jews; NADPH oxidase; NCF1; p47(phox)

Mesh:

Substances:

Year:  2015        PMID: 26460255     DOI: 10.1016/j.bcmd.2015.07.014

Source DB:  PubMed          Journal:  Blood Cells Mol Dis        ISSN: 1079-9796            Impact factor:   3.039


  6 in total

1.  A Founder Effect of c.257 + 2T > C Mutation in NCF2 Gene Underlies Severe Chronic Granulomatous Disease in Eleven Patients.

Authors:  Khaoula Ben-Farhat; Imen Ben-Mustapha; Meriem Ben-Ali; Karen Rouault; Saber Hamami; Najla Mekki; Amel Ben-Chehida; Beya Larguèche; Zohra Fitouri; Selim Abdelmoula; Monia Khemiri; Mohamed-Neji Guediche; Samir Boukthir; Sihem Barsaoui; Jalel Chemli; Mohamed-Ridha Barbouche
Journal:  J Clin Immunol       Date:  2016-05-25       Impact factor: 8.317

2.  Analysis of Chronic Granulomatous Disease in the Kavkazi Population in Israel Reveals Phenotypic Heterogeneity in Patients with the Same NCF1 mutation (c.579G>A).

Authors:  Baruch Wolach; Ronit Gavrieli; Martin de Boer; Karin van Leeuwen; Ofir Wolach; Galia Grisaru-Soen; Arnon Broides; Amos Etzioni; Raz Somech; Dirk Roos
Journal:  J Clin Immunol       Date:  2018-02-06       Impact factor: 8.317

3.  Microsatellite (SSR) amplification by PCR usually led to polymorphic bands: Evidence which shows replication slippage occurs in extend or nascent DNA strands.

Authors:  Abasalt Hosseinzadeh-Colagar; Mohammad Javad Haghighatnia; Zahra Amiri; Maryam Mohadjerani; Majid Tafrihi
Journal:  Mol Biol Res Commun       Date:  2016-09

4.  Second Report of Chronic Granulomatous Disease in Jordan: Clinical and Genetic Description of 31 Patients From 21 Different Families, Including Families From Lybia and Iraq.

Authors:  Faris Ghalib Bakri; Michelle Mollin; Sylvain Beaumel; Bénédicte Vigne; Nathalie Roux-Buisson; Adel Mohammed Al-Wahadneh; Raed Mohammed Alzyoud; Wail Ahmad Hayajneh; Ammar Khaled Daoud; Mohammed Elian Abu Shukair; Mansour Fuad Karadshe; Mahmoud Mohammad Sarhan; Jamal Ahmad Wadi Al-Ramahi; Julien Fauré; John Rendu; Marie Jose Stasia
Journal:  Front Immunol       Date:  2021-03-05       Impact factor: 7.561

Review 5.  Recent advances in understanding and treating chronic granulomatous disease.

Authors:  Andrew Gennery
Journal:  F1000Res       Date:  2017-08-11

6.  The Israeli national population program of genetic carrier screening for reproductive purposes. How should it be continued?

Authors:  Joël Zlotogora
Journal:  Isr J Health Policy Res       Date:  2019-12-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.